Smith Group Asset Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Smith Group Asset Management’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-967	Closed	-$1.45M	–	449
2014 Q3	$1.45M	Sell	967 -4	-0.4%	-$5.79K	0.05%	165
2014 Q2	$1.33M	Sell	971 -45	-4%	-$52.2K	0.05%	170
2014 Q1	$1.41M	Sell	1,016 -6	-0.6%	-$6.98K	0.05%	170
2013 Q4	$1.02M	Sell	1,022 -5	-0.5%	-$5.17K	0.04%	177
2013 Q3	$1.07M	Sell	1,027 -107	-9%	-$114K	0.04%	176
2013 Q2	$1.23M	Buy	+1,134	New	+$1.26M	0.05%	176

Other funds holding VIRX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Smith Group Asset Management's VIRX Position: Q4 2014 in Review

Smith Group Asset Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2014, closing a stake of 967 shares — an estimated $1.45M sold.

Smith Group Asset Management first reported a position in VIRX in Q2 2013 and held it in 6 quarters. The position peaked at $1.45M in Q3 2014. 78 funds tracked by Wall St. Rank hold VIRX as of Q4 2014.

Smith Group Asset Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2014 after selling out during the quarter.
Smith Group Asset Management sold 967 Viracta Therapeutics, Inc. Common Stock shares in Q4 2014, an estimated $1.45M.
Smith Group Asset Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 6 quarters.
Smith Group Asset Management's Viracta Therapeutics, Inc. Common Stock position peaked at $1.45M in Q3 2014.
78 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2014.

Based on Smith Group Asset Management's 13F filing for Q4 2014, filed 27 Jan 2015.